A Cross-over Response to Sequential Use of Sunitinib after Sorafenib in a Patient with Metastatic Renal Cell Carcinoma

Clinical Oncology

Volumn 21, Issue 8, 2009, Pages 633-634

  Richards, T M ^a   Plowman, P N ^a   Reznek, R ^a   Ball, S A ^a  

^a ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

SORAFENIB; SUNITINIB;

ADULT; CANCER RELAPSE; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; HUMAN; KIDNEY CARCINOMA; LETTER; LIVER METASTASIS; MALE; METASTASIS POTENTIAL; NEPHRECTOMY; PRIORITY JOURNAL; TREATMENT OUTCOME; TUMOR VOLUME;

ANTINEOPLASTIC AGENTS; BENZENESULFONATES; CARCINOMA, RENAL CELL; HUMANS; INDOLES; KIDNEY NEOPLASMS; LIVER NEOPLASMS; MIDDLE AGED; PYRIDINES; PYRROLES; TREATMENT OUTCOME;

EID: 69449105129     PISSN: 09366555     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clon.2009.03.001     Document Type: Letter

References (5)

1. Walther J.C., Khorshid M., Gaya A., and Plowman P.N. Cross-over response to erlotinib of brain metastastic disease from bronchial adenocarcinoma after gefitinib failure, and an unusual rash. Clin Oncol 18 (2006) 637-639
2. Sablin M.P., Bouaita L., Balleyguier C., et al. Sequential use of sorafenib and sunitinib in renal cancer: retrospective analysis in 90 patients. Proc Am Soc Clin Oncol J Clin Oncol 25 (2007) 5038
3. Dham A., and Dudek A.Z. Sequential therapy with sorafenib and sunitinib in renal cell carcinoma. Proc Am Soc Clin Oncol J Clin Oncol 25 (2007) 5106
4. Karaman M.W., Herrgar S., Treiber D.K., et al. A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol 26 (2008) 127-132
5. Temsirolimus vs sorafenib as second-line therapy in patients with advanced RCC who have failed first-line sunitinib. Available from: http://clinicaltrials.gov/ct2/show/NCT00474786.